Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook-square
  • x
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
Home > About Us > Legislation > Notifications > Notification of Draft Amendments in the Drugs (Research) Rules, 1978

Notification of Draft Amendments in the Drugs (Research) Rules, 1978

Yasir Mahmood Notifications September 11, 2026September 11, 2026

The comments of stakeholders are invited on the proposed amendments in the Drugs (Research) Rules, 1978. Comments or suggestions may be forwarded to the Drug Regulatory Authority of Pakistan for consideration within seven days of the publication of the notification, either by post or by email at director.legal∂dra.gov.pk

Notification of Draft Amendments in the Drugs (Research) Rules, 1978Download

Share this:

  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • ← Post-Registration Variation Guidelines for Pharmaceutical and Biological Products
  • Guidance on the Registration Pathways for Pharmaceutical and Biological Drugs for Human Use →
  • DRAP at a Glance
    • What We Do?
    • Vision & Mission
    • CEO’s Message
  • Organization
    • Organizational Structure
    • Divisions
    • Policy Board
    • Members of Authority
    • Information and Transparency
    • Strategic Plan 2026-2030
  • Legislation
    • Acts
    • Rules
    • Regulations
    • SROs
    • Notifications
  • Boards and Committees
    • Central Licensing Board
    • Registration Board
    • Medical Devices Board
    • Enlistment Evaluation Committee
    • Clinical Studies Committee
    • Pharmacovigilance RAE Committee
    • Committee on Advertisements
  • Quality Management System
    • Quality Policy
    • Management Reviews

Quick Navigation

     
  • Registered Drugs Index
  • Drug Pricing Index
  • List of Pharmaceutical Units

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:00AM to 04:00PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem